Literature DB >> 21055727

Extrapancreatic roles of glimepiride on osteoblasts from rat manibular bone in vitro: Regulation of cytodifferentiation through PI3-kinases/Akt signalling pathway.

Pan Ma1, Wei Xiong, Hongchen Liu, Junli Ma, Bin Gu, Xia Wu.   

Abstract

Glimepiride, a third-generation sulfonylurea, has also been reported to have extrapancreatic functions including activation of PI3-kinase (PI3K) and Akt in rat adipocytes, skeletal muscle and endothelial cells. It is tempting to speculate that glimepiride would improve bone-implant contact in diabetic patients by mediating the activity of GLUT1 and 3 via the PI3K/Akt pathway. In this study, we investigated the effects of glimepiride on rat mandible osteoblasts cultured under two different levels of glucose. Cell proliferation was determined by the MTT assay. The supernatant was used to measure alkaline phosphatase (ALP) activity. Glucose uptake was determined by measuring the rate of 2-deoxy-d-glucose (2-DG) uptake. Western blotting was performed used to determine collagen I and PI3K/Akt expression. RT-PCR was performed used to determine osteocalcin (OCN) mRNA expression. We found that hyperglycemia down-regulated proliferation, ALP activity, OCN mRNA and GLUT3 protein expression in rat osteoblasts, and upregulated collagen I and GLUT1 protein expressions. Glimepiride enhanced the proliferation, ALP activity and OCN mRNA levels, and upregulated collagen I and GLUT1 and 3 protein expressions of rat osteoblasts at two different glucose concentrations. This study also provides the first evidence that glimepiride stimulates the phosphorylation of PI3K/Akt in osteoblasts and ameliorated the damage caused by high concentrations of glucose through the PI3K/Akt pathway.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055727     DOI: 10.1016/j.archoralbio.2010.10.009

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  7 in total

1.  Reduced cell proliferation and neuroblast differentiation in the dentate gyrus of high fat diet-fed mice are ameliorated by metformin and glimepiride treatment.

Authors:  Dae Young Yoo; Woosuk Kim; Sung Min Nam; Ki-Yeon Yoo; Choong Hyun Lee; Jung Hoon Choi; Moo-Ho Won; In Koo Hwang; Yeo Sung Yoon
Journal:  Neurochem Res       Date:  2011-08-05       Impact factor: 3.996

2.  High glucose microenvironments inhibit the proliferation and migration of bone mesenchymal stem cells by activating GSK3β.

Authors:  Bo Zhang; Na Liu; Haigang Shi; Hao Wu; Yuxuan Gao; Huixia He; Bin Gu; Hongchen Liu
Journal:  J Bone Miner Metab       Date:  2015-04-04       Impact factor: 2.626

Review 3.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

4.  Glimepiride promotes osteogenic differentiation in rat osteoblasts via the PI3K/Akt/eNOS pathway in a high glucose microenvironment.

Authors:  Pan Ma; Bin Gu; Wei Xiong; Baosheng Tan; Wei Geng; Jun Li; Hongchen Liu
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

5.  High glucose inhibits osteogenic differentiation through the BMP signaling pathway in bone mesenchymal stem cells in mice.

Authors:  Juncheng Wang; Bin Wang; Ying Li; Dongsheng Wang; E Lingling; Yang Bai; Hongchen Liu
Journal:  EXCLI J       Date:  2013-06-27       Impact factor: 4.068

Review 6.  Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.

Authors:  A Palermo; L D'Onofrio; R Eastell; A V Schwartz; P Pozzilli; N Napoli
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

7.  Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats.

Authors:  Mohamed M Amin; Gihan F Asaad; Rania M Abdel Salam; Hanan S El-Abhar; Mahmoud S Arbid
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.